High-grade serous carcinoma (HGSC) is the most common and lethal form of ovarian cancer. While many patients initially respond to chemotherapy, relapse is almost inevitable. Improving outcomes requires a deeper understanding of tumour evolution over time and the impact of treatment on both cancer cells and their microenvironment. The PIONEER networking event will unite clinicians, researchers, data scientists, industry, patient representatives and policy experts to address this challenge. The meeting aims to integrate patient data, better align laboratory models with clinical outcomes, overcome barriers such as drug resistance and data sharing, and develop a shared strategy and European network to advance personalised therapies for ovarian cancer.

• Research on HGSC is limited by the fragmentation of data, limited interoperability, and ethical/legal constraints on patient-derived datasets.
• The project will aim to overcome these limits by bringing together experts from the DYNAMITE and PARIS project, who collaboratively organise the networking event
• The event is going to be held in June 2026 in Copenhagen, Denmark
• The main goal is harmonising methodologies for longitudinal sampling, multiomics profiling, and computational reconstruction of tumour evolution.
• Another goal is to facilitate collaboration to discover candidate resistance mechanisms in patient samples and validate them in patient-derived organoids.
• towards that goal, protocols for model standardisation needs to be established, ensuring that findings from patient-derived organoids and experimental systems faithfully reflect patient disease trajectories.
• In collaboration with clinical stakeholders the consortium will develop consensus strategies for the integration of multi-modal datasets for clinical translation